Trinity J. Bivalacqua
@tbivala1
I am a urologic cancer surgeon and sexual medicine specialist at the University of Pennsylvania. I run a basic translational research lab
ID: 3407922261
08-08-2015 00:20:49
191 Tweet
1,1K Followers
262 Following
Starting now: Day 2 #AIBCCR On program: Targeting Metastatic Disease William Y. Kim et al BCG and beyond Molly Ingersoll Max Kates Trinity J. Bivalacqua Joshua Meeks Gary Steinberg
Always enjoy sharing the annual Amer. Urol. Assn. Early Career Investigators Workshop class & faculty! So grateful to our dedicated faculty and congratulations to all of our early career investigators for making this commitment to your research funding success! Dr. Steven Kaplan
A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non–muscle-invasive Bladder Cancer buff.ly/3mCKhIF Max Kates Kara Lombardo Andres Matoso Andrew Gabrielson Jean Hoffman-Censits David McConkey Trinity J. Bivalacqua Andres Matoso
Huge momentum thx to @Svet_MD addressing organ preservation in women. Long history of this The Johns Hopkins Brady Urological Institute, recent pub by Sunil Patel MD Trinity J. Bivalacqua: sciencedirect.com/science/articl… Now doing organ pres with opportunistic salpingectomy. More data needed auajournals.org/doi/10.1097/JU… Claire de la Calle
Max Kates @Svet_MD The Johns Hopkins Brady Urological Institute Trinity J. Bivalacqua Claire de la Calle Could not agree more. These in addition to publication by Kelly Bree, highlighting the importance of changing the dogma in female cystectomies.
A new candidate vaccine against NMIBC in a multi institutional study in close collaboration with Trinity J. Bivalacqua Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against… disq.us/t/457gd6d
The Johns Hopkins Brady Urological Institute Alok Kumar Singh monali praharaj Trinity J. Bivalacqua nature.com/articles/s4146…
Congrats to my past mentee Meera Chappidi and current mentee Ridwan Alam on their much deserved grants from the Urology Care Foundation
Former The Johns Hopkins Brady Urological Institute co-residents caught out in the wild 🤙 👍 #AUA22
#urotwitter What are the 50 Landmark papers urologists should know? for a new CRC Press book. These can be a new procedure, evaluating effects of new treatments/techniques, new classification system or insights into disease. With great coauthors Claire Taylor Yasmin Abu-Ghanem
Intermediate-risk Non–muscle-invasive BC: Updated Consensus Definition and Management Recommendations from the International BC Group buff.ly/3fJVl5N Wei Shen Tan Gary Steinberg Roger Li Shahrokh F. Shariat Morgan Roupret Trinity J. Bivalacqua Sarah P. Psutka MD MS Stephen B. Williams, MD, MBA, MS, FACHE Cookson, Michael Ashish M. Kamat, MD, MBBS
Updated results from #CORE1 using pembro + cretostimogene (cg0070) in BCG unresponsive CIS 👉 Overall CR = 85% (29/34) 👉CR @ 12 months = 68% (17/25) 👉AE profile similar to monotherapy trials Gary Steinberg Ashish M. Kamat, MD, MBBS Trinity J. Bivalacqua CG Oncology, Inc. onclive.com/view/phase-2-d…
Roger Li Ashish M. Kamat, MD, MBBS Trinity J. Bivalacqua CG Oncology, Inc. Outstanding combo replication selective cretostimogene plus checkpoint inhibitor Proof of principle and improving patient outcomes with very high NMIBC #gdsfellows Stephanie Chisolm, PhD
Long awaited data from SWOG Cancer Research Network 1011 investigating value of ELND in MIBC 👉no diff in DFS w ELND 👉more LN yield 👉more SAE w ELND 👉? benefit in pT3/4 Congrats to Dr. Seth Lerner and the entire team 👏👏👏 #ASCO23
![<a href="/tbivala1/">Trinity J. Bivalacqua</a> give his take home messages for the 1] #SWOGS1011 surgical trial of standard vs extended lymphadenectomy 2] the #VESPER trial of dd-MVAC vs GC as perioperative chemo for MIBC 3] #CheckMate914 Adjuvant Nivo/Ipi in high risk #RCC after nephrectomy <a href="/ASCO/">ASCO</a> #ASCO23](https://pbs.twimg.com/media/Fx4eR5oXsAAntco.jpg "Andrea Apolo, M.D. (@apolo_andrea) on Twitter photo <a href=\"/tbivala1/\">Trinity J. Bivalacqua</a> give his take home messages for the 1] #SWOGS1011 surgical trial of standard vs extended lymphadenectomy 2] the #VESPER trial of dd-MVAC vs GC as perioperative chemo for MIBC 3] #CheckMate914 Adjuvant Nivo/Ipi in high risk #RCC after nephrectomy <a href=\"/ASCO/\">ASCO</a> #ASCO23")
Honored to discuss ASCO (pinch hitting for Ashish M. Kamat, MD, MBBS ) S1011 trial results demonstrating NO DFS/OS for EPLND splernerMD concludes that SLND is now standard of care for T2-T4N0 patients undergoing RC. >LN counts, >morbidity. Predominantly T2 cohort with 57%NAC!
Comprehensive review article on adaptive immunity in GU Cancers led by Madhuri Koti Trinity J. Bivalacqua Peter Black Matt Galsky Molly Ingersoll IBCG IBCN #bladdercancer